Primary tabs

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A prospective multicenter double-randomised double-blind 2-parallel groups phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine to gemcitabine in combination with placebo followed as...

To compare the efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine in treatment of patients with advancedmetastatic pancreatic cancer

FieldValue
Modified
2020-03-29
Release Date
2018-06-12
Identifier
1e4d3d04-171f-452a-80a7-85f19d9a4bc8
License
Public Access Level
Public